183 related articles for article (PubMed ID: 24934312)
1. Inter-ethnic differences in genetic polymorphisms of xenobiotic-metabolizing enzymes (CYP1A1, CYP2D6, NAT1 and NAT2) in healthy populations: correlation with the functional in silico prediction.
Khlifi R; Ben Salah G; Chakroun A; Hamza-Chaffai A; Rebai A
Mol Biol Rep; 2014 Sep; 41(9):5735-43. PubMed ID: 24934312
[TBL] [Abstract][Full Text] [Related]
2. Association of CYP1A1 and CYP2D6 gene polymorphisms with head and neck cancer in Tunisian patients.
Khlifi R; Chakroun A; Hamza-Chaffai A; Rebai A
Mol Biol Rep; 2014; 41(4):2591-600. PubMed ID: 24449363
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in XRCC1, ERCC2, and ERCC3 DNA repair genes, CYP1A1 xenobiotic metabolism gene, and tobacco are associated with bladder cancer susceptibility in Tunisian population.
Feki-Tounsi M; Khlifi R; Louati I; Fourati M; Mhiri MN; Hamza-Chaffai A; Rebai A
Environ Sci Pollut Res Int; 2017 Oct; 24(28):22476-22484. PubMed ID: 28803404
[TBL] [Abstract][Full Text] [Related]
4. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers.
Khlifi R; Messaoud O; Rebai A; Hamza-Chaffai A
Biomed Res Int; 2013; 2013():582768. PubMed ID: 24151610
[TBL] [Abstract][Full Text] [Related]
6. Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma.
Khedhaier A; Hassen E; Bouaouina N; Gabbouj S; Ahmed SB; Chouchane L
BMC Cancer; 2008 Apr; 8():109. PubMed ID: 18423013
[TBL] [Abstract][Full Text] [Related]
7. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract][Full Text] [Related]
8. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians.
Gra O; Mityaeva O; Berdichevets I; Kozhekbaeva Z; Fesenko D; Kurbatova O; Goldenkova-Pavlova I; Nasedkina T
Genet Test Mol Biomarkers; 2010 Jun; 14(3):329-42. PubMed ID: 20373852
[TBL] [Abstract][Full Text] [Related]
9. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.
Krajinovic M; Ghadirian P; Richer C; Sinnett H; Gandini S; Perret C; Lacroix A; Labuda D; Sinnett D
Int J Cancer; 2001 Apr; 92(2):220-5. PubMed ID: 11291049
[TBL] [Abstract][Full Text] [Related]
10. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues.
Kim SJ; Kang HS; Jung SY; Min SY; Lee S; Kim SW; Kwon Y; Lee KS; Shin KH; Ro J
J Mol Med (Berl); 2010 Nov; 88(11):1123-31. PubMed ID: 20628863
[TBL] [Abstract][Full Text] [Related]
11. Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study.
Perera FP; Tang D; Brandt-Rauf P; Santella RM; Mooney LV; Tu YH; Bendkowska I; Bell DA
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1417-9. PubMed ID: 16835348
[No Abstract] [Full Text] [Related]
12. Polymorphism p.Val231Ile alters substrate selectivity of drug-metabolizing arylamine N-acetyltransferase 2 (NAT2) isoenzyme of rhesus macaque and human.
Tsirka T; Boukouvala S; Agianian B; Fakis G
Gene; 2014 Feb; 536(1):65-73. PubMed ID: 24333853
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus.
von Schmiedeberg S; Fritsche E; Rönnau AC; Specker C; Golka K; Richter-Hintz D; Schuppe HC; Lehmann P; Ruzicka T; Esser C; Abel J; Gleichmann E
Adv Exp Med Biol; 1999; 455():147-52. PubMed ID: 10599336
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Mota P; Silva HC; Soares MJ; Pego A; Loureiro M; Cordeiro CR; Regateiro FJ
J Cancer Res Clin Oncol; 2015 May; 141(5):851-60. PubMed ID: 25388590
[TBL] [Abstract][Full Text] [Related]
15. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay.
Labuda D; Krajinovic M; Richer C; Skoll A; Sinnett H; Yotova V; Sinnett D
Anal Biochem; 1999 Nov; 275(1):84-92. PubMed ID: 10542112
[TBL] [Abstract][Full Text] [Related]
17. Population variability of rhesus macaque (Macaca mulatta) NAT1 gene for arylamine N-acetyltransferase 1: Functional effects and comparison with human.
Boukouvala S; Chasapopoulou Z; Giannouri D; Kontomina E; Marinakis N; Rizou SV; Stefani I; Tsirka T; Veyssière C; Zaliou S; Sabbagh A; Crouau-Roy B; Fakis G
Sci Rep; 2019 Jul; 9(1):10937. PubMed ID: 31358821
[TBL] [Abstract][Full Text] [Related]
18. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.
Agúndez JA; Martínez C; Olivera M; Gallardo L; Ladero JM; Rosado C; Prados J; Rodriguez-Molina J; Resel L; Benítez J
Br J Cancer; 1998 Nov; 78(10):1361-7. PubMed ID: 9823980
[TBL] [Abstract][Full Text] [Related]
19. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility.
Daly AK; Cholerton S; Armstrong M; Idle JR
Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):55-61. PubMed ID: 7698086
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.
Hein DW; Doll MA; Fretland AJ; Leff MA; Webb SJ; Xiao GH; Devanaboyina US; Nangju NA; Feng Y
Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):29-42. PubMed ID: 10667461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
